Ironwood to look for alternative paths after FDA asks for another Phase 3

Ironwood Pharmaceuticals is now working with Goldman Sachs in its hunt for company alternatives after getting regulatory feedback from the FDA. The Boston drugmaker hoped to get the agency's blessing for apraglutide, its drug for ...